MLchartDataset catalogue

Zirabev

Term · Oncology and biomedicine · MLC-T-ONC-009485

A drug that contains the active ingredient bevacizumab and is used to treat many different types of cancer. Zirabev is used alone or with other drugs to treat certain types of cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), and glioblastoma (a type of brain cancer). It is also being studied in the treatment of other types of cancer. Zirabev binds to a protein called VEGF, which may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.

Table 1. Record
IdentifierMLC-T-ONC-009485
FieldOncology and biomedicine
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-009485",
  "term": "Zirabev",
  "field": "Oncology and biomedicine",
  "definition": "A drug that contains the active ingredient bevacizumab and is used to treat many different types of cancer. Zirabev is used alone or with other drugs to treat certain types of cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), and glioblastoma (a type of brain cancer). It is also being studied in the treatment of other types of cancer. Zirabev binds to a protein called VEGF, which may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.",
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/zirabev/"
}

Record 17,650 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.